PRRT or Peptide Receptor Radionuclide Therapy may be used to treat patients with Neuroendocrine Tumours (NETs) including Carcinoids, Islet Cell Carcinoma of the Pancreas, Small Cell Carcinoma of the Lung, Pheochromocytoma (a rare tumor that forms in the adrenal glands), Gastro-enteropancreatic (stomach, intestines, and pancreas) Neuroendocrine Tumours, and Rare Thyroid Cancers that are unresponsive to treatment with radioiodine.
Search Keywords / Tags: Peptide Receptor Radionuclide Therapy,